Randolf Kerschbaumer

Co-Founder, President & Chief Executive Officer OncoOne

Seminars

Wednesday 2nd December 2026
Breaking the Preclinical-to-Clinical Bottleneck: Advancing Novel Theranostic Radiopharmaceuticals into First-in-Human Trials
12:00 pm
  • Navigating the transition from a completed preclinical package into first-in-human development, identifying the critical hurdles that emerge as novel theranostic programmes approach the clinic
  • Coordinating clinical, CMC and regulatory requirements to build a cohesive translational strategy and avoid delays between preclinical completion and patient dosing
  • Applying lessons learned from preparing an early-stage radiopharmaceutical programme for Phase I to anticipate translational challenges earlier and accelerate novel theranostics towards patients
Wednesday 2nd December 2026
Re-Engineering the Therapeutic Window: Can Pre-Targeting Overcome the Fundamental Limitations of Conventional Radiopharmaceuticals?
1:30 pm
  • Examining how the pharmacokinetic coupling of tumor targeting and radionuclide delivery constrains the therapeutic window of conventional radiopharmaceuticals
  • Exploring how pre-targeting separates tumor localization from radionuclide administration to improve tumor-to-non-tumor tissue exposure and enable more flexible radionuclide delivery 
  • Sharing lessons learned from candidate selection, platform optimization, and preclinical development in advancing next-generation pre-targeting technologies
  • Identifying the target characteristics and disease settings most likely to benefit from pre-targeting and unlock previously inaccessible therapeutic opportunities
Randolf Kerschbaumer-1mb